Recent studies, among them a meta-analysis on more than 100 randomized trials, have surprisingly revealed that patients who take a CD26 inhibitor for the treatment of type 2 diabetes showed a decreased risk for the development of neoplasms (6). Here, DPP4 is linked to type 2 diabetes mellitus.